MDT
Medtronic plc · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.44M | $115.59M | n/a | n/a |
| Q2 2026 | 172 | +1 | 851.51M | $67.87B | +6 | −7 |
| Q1 2026 | 176 | +1 | 881.81M | $77.21B | +3 | −3 |
| Q4 2025 | 174 | 0 | 922.24M | $88.62B | +1 | n/a |
| Q3 2025 | 25 | -2 | 519.60M | $49.51B | n/a | −3 |
| Q2 2025 | 25 | +1 | 407.26M | $35.53B | +1 | n/a |
| Q1 2025 | 21 | 0 | 149.92M | $13.50B | +1 | −1 |
| Q4 2024 | 21 | -1 | 154.76M | $12.40B | n/a | −1 |
| Q3 2024 | 21 | +1 | 104.49M | $9.40B | +1 | n/a |
| Q2 2024 | 20 | n/a | 97.49M | $7.67B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 26.86M | n/a | $2.11B | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 2 | Wellington Management ✦ | 21.24M | n/a | $1.67B | 0.3% | n/c | 1 | SEC ↗ ×7 |
| 3 | Norges Bank ✦ (passive) | 15.58M | n/a | $1.23B | 0.2% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 6.98M | n/a | $549.59M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 5 | Dodge & Cox ✦ | 6.79M | n/a | $534.56M | 0.3% | n/c | 1 | SEC ↗ |
| 6 | Fisher Asset Management ✦ | 5.28M | n/a | $415.93M | 0.2% | n/c | 1 | SEC ↗ |
| 7 | Arrowstreet Capital ✦ | 4.75M | n/a | $373.52M | 0.3% | n/c | 1 | SEC ↗ |
| 8 | Millennium Management ✦ | 1.99M | n/a | $156.57M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 1.45M | n/a | $113.49M | 0.2% | n/c | 1 | SEC ↗ ×4 |
| 10 | Bridgewater Associates ✦ | 1.38M | n/a | $108.54M | 0.6% | n/c | 1 | SEC ↗ |
| 11 | Adage Capital Partners ✦ | 1.10M | n/a | $86.48M | 0.2% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 1.05M | n/a | $82.80M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | PRIMECAP Management ✦ | 870.33K | n/a | $68.50M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 636.34K | n/a | $50.09M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Baillie Gifford ✦ | 432.56K | n/a | $34.05M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 16 | Gotham Asset Management ✦ | 340.67K | n/a | $26.81M | 0.3% | n/c | 1 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 302.45K | n/a | $23.81M | 0.1% | n/c | 1 | SEC ↗ |
| 18 | Marshall Wace ✦ | 267.94K | n/a | $21.09M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 19 | D. E. Shaw & Co. ✦ | 190.32K | n/a | $14.98M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | GAMCO Investors ✦ | 3.92K | n/a | $308,937 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 2,204 holders, 1.04B shares, $87.65B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 10.42K sh · $1.00M
Officer, Director · 50.00K sh · $4.75M
Officer · 1.48K sh · $138,883
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology